View
3
Download
0
Category
Preview:
Citation preview
JP MORGAN 2021 | FOR INVESTORS ONLY
MICHAEL R. MINOGUE
CHAIRMAN, PRESIDENT & CEO
JP MORGAN 2021 | FOR INVESTORS ONLY
LEGAL DISCLAIMERS2
This presentation contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future
opportunities, the Company’s guidance for future financial performance and expected regulatory approvals. Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports
on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
U.S Food and Drug Administration Approvals, Clearances & Authorizations
● The Impella 2.5® and Impella CP® devices are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen
blocked coronary arteries.
● The Impella 2.5®, Impella CP®, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock,Tha and have the
unique ability to enable native heart recovery, allowing patients to return home with their own heart.
● Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0
and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac
decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella LV Support Systems have been authorized
for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the
Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
● The Impella RP® is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.
● The Impella RP is also authorized for emergency use by healthcare providers (HCPs) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients with a body surface area ≥1.5 m2, for the
treatment of acute right heart failure or decompensation caused by complications related to coronavirus disease 2019 (COVID‐19), including pulmonary embolism (PE). The Impella RP has not been cleared or approved for the treatment of
acute right heart failure or decompensation caused by complications related to COVID-19. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized
only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or
revoked sooner.
● The Abiomed Breethe OXY-1 System™ is cleared by the U.S. Food and Drug Administration (FDA) to provide extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary
bypass up to six (6) hours in duration.
● Under guidance issued by FDA, on April 6, 2020, the Abiomed Breethe OXY-1 System is now permitted to be used temporarily in the U.S. for ECMO therapy greater than six hours. Therefore, it now has a limited indication modification for use
longer than six hours in an extracorporeal membrane oxygenation (ECMO) circuit to treat patients who are experiencing acute temporary respiratory or acute cardiopulmonary failure. This limited indication modification for ECMO therapy
greater than six hours has not been cleared or approved by FDA and is in effect only for the duration of the public health emergency related to COVID-19 as declared by the U.S. Department of Health and Human Services (HHS).
● The Impella XR Sheath set is cleared by the U.S. FDA and is intended for use for the percutaneous introduction of the Impella 2.5 Catheter and ancillary devices.
In addition, there are other WARNINGS and PRECAUTIONS associated with Abiomed devices. Visit http://www.abiomed.com/important-safety-information to learn more.
Impella ECP™ is an investigational device, limited by Federal law to investigational use only. The Impella BTR™ and Impella Pediatric™ are in development and are not approved for use or sale.
The ABIOMED logo, ABIOMED, Impella 2.5, Impella CP, Impella RP, Impella 5.0, Impella LD, Impella 5.5 SmartAssist Platform, and Recovering Hearts. Saving Lives are registered trademarks of Abiomed, Inc. in the U.S.A. and certain
foreign countries. Impella ECP, Impella BTR, cVAD Study, and Automated Impella Controller are pending trademarks of Abiomed, Inc.
JP MORGAN 2021 | FOR INVESTORS ONLY
IMPELLA® HEART PUMPS: BREAKTHROUGH TECHNOLOGY3
>170,000 patients treated world-wide;
10 Clinical Guidelines; ~900 publications
✓ Exclusive FDA US Approvals: High-Risk PCI (2015)
AMI Cardiogenic Shock (2016)
Impella RP® for Right Heart Failure (2017)
Cardiomyopathy/Myocarditis Shock (2018)
Expanded High-Risk PCI; SmartAssist® (2018)
Emergency Use Authorizations (EUA-2020)
✓ CMS Medicare, 4 DRG Codes:Reimbursement for implant, explant, transfer,
ECpella & biventricular Impella at 1,400+ US
hospitals
✓ Approved in Europe and Japan (CE Mark 2002; PMDA 2016)
✓ >$600M R&D (1,070 patents and 856 pending)
Jan 2021
*Click picture for Impella animation video
JP MORGAN 2021 | FOR INVESTORS ONLY
4
THE ABIOMED MISSION
To recover heart muscle and save lives with percutaneous heart pump
and oxygenation technologies, enabling safer, more effective treatment
and therapies for high-risk, urgent and emergent patients.
JP MORGAN 2021 | FOR INVESTORS ONLY
THE ABIOMED MISSION5
Click Here for Dr. Babu Eladasari’s Full Patient Story
JP MORGAN 2021 | FOR INVESTORS ONLY
ABIOMED OVERVIEW (NASDAQ: ABMD)6
Key Medical Device Countries: Impella® Products
Approved; ABMD Direct Distribution/Coverage;
Dedicated Impella Reimbursement
Next Tier Opportunities: Impella® Products
Approved; No / Limited Distribution Coverage
GLOBAL HQ: MASSACHUSETTS, USA
200,000+ sq. ft. with Manufacturing
Founded in 1981
Global Employees ~1,600
JAPANESE HQ: TOKYO
First Patient Treated: 2017
EUROPEAN HQ: AACHEN, GERMANY
71,000 sq. ft. with Manufacturing
JP MORGAN 2021 | FOR INVESTORS ONLY
STRONG 16 YEAR REVENUE TRACK RECORD7
$38M$73M $86M $101M $126M
$158M $184M$230M
$330M
$445M
$594M
$769M
$841M
FY'05 FY'09 FY'10 FY'11 FY'12 FY'13 FY'14 FY'15 FY'16 FY'17 FY'18 FY'19 FY'20
Note: Fiscal Year ends March 31.
FDA Impella 510(k) Clearance Profitable
FDA Approval
Right-Heart Failure
MHLW Approval in Japan &
FDA Approval AMI / CGS
FDA Approval
Impella 5.5®
FDA Approval Impella
CP®
SmartAssist®
FDA Approval
Protected PCI
JP MORGAN 2021 | FOR INVESTORS ONLY
DELIVERING STRONG MARGIN & CASH PERFORMANCE8
OPERATING INCOME & MARGIN
40% CAGR
$65M
$90M
$157M
$225M
$249M
FY'16 FY'17 FY'18 FY'19 FY'20
OM% 20% 27% 29% 30%20%
CASH* - NO DEBT
32% CAGR
$213M
$277M
$400M
$513M
$651M
FY'16 FY'17 FY'18 FY'19 FY'20
Debt: $0
*Total Cash, short-term and long-term
marketable securities
GROSS MARGIN
AVERAGING +80% MARGINS
85% 84% 83% 83% 82%
FY'16 FY'17 FY'18 FY'19 FY'20
JP MORGAN 2021 | FOR INVESTORS ONLY
ABIOMED: THE HEART RECOVERY COMPANY9
RECOVERING HEARTS.
SAVING LIVES.®
1. Creating the Innovation for the
Field of Heart Recovery with the
Impella® Heart Pump Platform and
Breethe Oxy-1 SystemTM
4. Sustaining Long-Term Growth
Driven by Innovation and Strong
Execution
2. Solving a Clinical Crisis
for Large and Growing
Patient Populations
3. Improving Patient Outcomes
by Leading in Clinical Research,
Education and 24/7 Hospital Support
1. Creating
the
InnovationJP MORGAN 2021 | FOR INVESTORS ONLY
Percutaneous Insertion
Not a Heart Pump
IABP
(1976*)
Percutaneous Insertion
Unloads the Heart
IMPELLA
(2008)
* IABP grandfathered in 1976
Perfuses the Body with
Oxygen, Loads the Heart
ECMO
(1980S)
ECPELLA
+
HISTORY OF HEART SUPPORT
1. Creating
the
InnovationJP MORGAN 2021 | FOR INVESTORS ONLY
ABIOMED 2.0 PLATFORM: IMPELLA AND ECMO11
Impella 2.5®
Impella RP®
Impella CP®
with SmartAssist®
RIGHT-HEART
PERCUTANEOUS INSERTION SURGICAL INSERTION
Impella 5.5®
with SmartAssist®
AIC WITH SMARTASSIST®
(AUTOMATED IMPELLA CONTROLLER)
24/7 Support Onsite, On-call, Online
Impella Connect®Clinical Support
Center
>400 Global Field Reps
ECMO
Breethe Oxy-1
SystemTM
510(k) Clearance 2020
Impella ECPTM
FDA EFS
JP MORGAN 2021 | FOR INVESTORS ONLY
ABIOMED: THE HEART RECOVERY COMPANY12
RECOVERING HEARTS.
SAVING LIVES.®
2. Solving a Clinical Crisis
for Large and Growing
Patient Populations
2. Solving a
Clinical Crisis
JP MORGAN 2021 | FOR INVESTORS ONLY
13
• American Heart Association: Heart Disease and Stroke Statistics—2015 Update
1. Einarson et al. Cardiovasc Diabetol (2018) 17:83
2. Sidney S et al. Association between aging of the US population and heart disease mortality from 2011-2017, JAMA Cardiol. doi. 10.1001/jamacardio.2019.4187
3. Historic Survival without Impella Support/Protocols:1990-2006: ~50% Mortality ; 2017 CULPRIT SHOCK Study: ~50% Mortality, NEJM ; Jeger, et al. Ann Intern
Med. 2008
4. Halkin A et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction, J Am Coll Cardiol
2005;45:1397–1405 ; Solomon et al. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure
Patients, Circulation 2005; Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection
fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003; 42: 736-42
5. Heart Disease Could Cost U.S. $1 Trillion Per Year By 2035: Report. https://health.usnews.com/health-care/articles/2017-02-14/heart-
disease-could-cost-us-1-trillion-per-year-by-2035-report
CORONARY ARTERY DISEASE (CAD) & HEART FAILURE (HF): A GROWING CRISIS
#1 CAUSE OF DEATH IN U.S IS CAD & HF>15M people & 875,000 deaths per year for CAD, increasing high-risk population
Obesity & Type II diabetes increasing heart attacks and kidney failure1
#1 cause of death for Type II diabetes patients is CAD / HF
#1 U.S. HEALTH EXPENDITURES: $555B in 2016 to $1.1T by 2035
5
#1 CARDIAC MORTALITY RISK: CARDIOGENIC SHOCK
~50% mortality rate for last 20+ years3 without Impella heart pumps
U.S. population 65+ years is increasing 44% by 20302, increasing high-risk population
Mortality also increasing in 45 – 65 year old population2
RESPIRATORY FAILURE (ADULT & PEDIATRIC)ARDS, H1N1, SARS, COVID-19
2. Solving a
Clinical Crisis
JP MORGAN 2021 | FOR INVESTORS ONLY
SURGICAL PROCEDURES
HEART SURGERY SUITE
WITH HEART & LUNG MACHINE
PERCUTANEOUS PROCEDURES
CATHERIZATION LAB (CATH)
WITH IMPELLA SUPPORT
FOR HIGH-RISK PCI &
CARDIOGENIC SHOCK
TREATING THE HEART – SURGICAL AND PERCUTANEOUS OPTIONS14
2. Solving a
Clinical Crisis
JP MORGAN 2021 | FOR INVESTORS ONLY
15
~10% U.S. PENETRATION FOR PROTECTED PCI & CARDIOGENIC SHOCK
HEART ATTACK
(STEMI)FDA STUDY ONGOING
HEART
FAILURE
CARDIOGENIC
SHOCK
PROTECTED
PCI
RESPIRATORY
FAILURE (ECMO)
~200K
U.S. PATIENTS10
>25K
U.S. PATIENTS9
>121K
U.S. PATIENTS1-8
202K
U.S. PATIENTS9
~100K
U.S. PATIENTS1
✓
FDA APPROVAL / CLEARANCE
✓ ✓ ✓
✓ OUS Current Addressable Market:
Germany: 25K, ~20% penetrated
Japan: 50K, ~4% penetrated
1. Mozaffarian D, et al. Circulation. 2015;131(4):e29-e322.
2. Gheorghiade M, Bonow RO. Circulation. 1998;97(3):282-289.
3. Braunwald E. JACC Heart Fail. 2013;1(1):1-20.
4. Patel MR, et al. N Engl J Med. 2010;362(10):886-895.
5. Cornwell LD, et al JAMA Surg. 2015;150(4):308-315.
6. Farmer SA, et al. JACC Cardiovasc Imaging. 2014;7(7):690-700.
7. Doshi D, et al. J Am Coll Cardiol. 2016;68(5):450-458.
8. O'Neill WW, et al. Circulation. 2012;126(14):1717-1727.
9. All payer data 2019, ±5% error including MedPar and NIS when available,
Definitive Healthcare
10. American Heart Association
JP MORGAN 2021 | FOR INVESTORS ONLY
ABIOMED: THE HEART RECOVERY COMPANY16
RECOVERING HEARTS.
SAVING LIVES.®
3. Improving Patient Outcomes
by Leading in Clinical Research,
Education and 24/7 Hospital Support
3. Improving
Patient
OutcomesJP MORGAN 2021 | FOR INVESTORS ONLY
IMPELLA & ECPELLA: IMPROVING OUTCOMES & LOWERING COSTS17
14. Dangas, et al. (2014). Am J Cardiol, 113 (2), 222-8.
15. O’Neill. (2018). Acute Coronary Syndromes, Cardiogenic Shock, and Hemodynamic Support, TCT
16. Milliman. (2017). US Organ and Tissue Transplant Cost Estimates and Discussion
17. Tehrani, et al. (2019). JACC, 73 (13), 1659-69.
18. Pappalardo, et al. (2017). Eur J Heart Fail, 19 (3), 404-412.
1. O’Neill, et al. (2012). Circulation, 126 (14), 1717-1727.
2. Burzotta, et al. (2019). Journal of Interventional Cardiology, 1–10.
3. Patel, et al. (2020). TCT Connect 2020 Abstract
4. O’Neill, et al. (2020). TCT Connect 2020 Presentation
5. Sawa. Annual Scientific Meeting, Japanese Circulation Society 2020
6. Stretch, et al. (2014). JACC, 64 (14), 1407-15.
7. Maini, et al. (2014). Expert Rev Pharmacoecon Outcomes Res, 14 (3), 403-16.
8. Gregory, et al. (2013). Am Health Drug Benefits, 6 (2), 88-99.
9. Gregory, et al. (2013). Journal of Managed Care Medicine, 16 (1), 61-69.
10. Aryana, et al. (2014). Heart Rhythm, 11 (7), 1122-30.
11. Wohns, et al. (2014). Innovations, 9 (1), 38-42.
12. Cheung, et al. (2012). J Am Coll Cardiol, 60 (17 Suppl B) B110. Abstract TCT-385.
13. Silver, et al. (2017). Nephron, 137 (4), 297–301.
Outcomes & Survival Improvement in Cardiogenic Shock
Higher SurvivalIn ECMO therapy with Impella
unloading (ECpella) 18
Up to
2x
Improved Survivalwith best practice protocol in
USA & Japan 5,15,17
77 to
82%
Native Heart Recoveryin 2018-2020 NCSI Study 4,15
90 to
99%
Cost-Effective Therapy
Cost Savingsfor each avoidance of heart
transplant or implantable LVAD 16
Up to
$887k
Hospital Stay ReductionIn elective, urgent and emergent
settings 7,8,9,10,11,12
2 to
11days
Hospital Cost Reductionper case in CAD and AMI-CS 6,13
$45 to
$54k
Improvement of LVEF at 90-day follow up 1,2,3
22 to
45%
Reduction of HFNYHA Class III/IV Symptoms
improvement in HR-PCI 1,3
58 to
80%
Less Adverse Eventsat 90 days (death, stroke, MI,
and/or repeat procedure) 1,14
29 to
47%
Quality of Life Improvement in High-Risk PCI
3. Improving
Patient
OutcomesJP MORGAN 2021 | FOR INVESTORS ONLY
IMPELLA CLINICAL EVIDENCE PATHWAY 510(K) TO FDA APPROVALS TO
CLASS I RECOMMENDATION GOALS
18
Real-World Evidence (RWE)
Pilot Single-arm Studies
Randomized Controlled Trials (RCTs)
High-Risk PCI Cardiogenic Shock
Established Safety & EffectivenessPilot Studies, RCTs, RWE
Attempted RCTs:(discontinued due to low enrollment)
Europella
Real-World Data
(2002, N=200)
PROTECT I
FDA Pilot
(2007, N=20)
PROTECT II
FDA Pivotal RCT
(2008, N=452)
USpella
Real-World Data
(2009, N=637)
ISAR Shock
EU CE Safety Study
(2006, N=20)
RECOVER I
FDA Pilot
(2007, N=17)
USpella
Real-World Data
(2009, N=401)
RECOVER
Right
Impella RP HDE Study
(2013, N=60)
RECOVER II
FDA Pivotal RCT
(2007, N=1)
IMPRESS
STEMI
FDA Pivotal RCT
(2007, N=1)
DANSHOCK
EU RCT
(2012, N=120)
510(k) Clearance
to FDA
Approvals (PMA)
Identify & Validate Best PracticesPhysician Studies, RWE, Registries, FDA PAS
PROTECT III
FDA Post Approval Study
(2017, N>1050)
CVAD Renal Protection Study
Real-World Data
(2019, N=223)
RECOVER III
FDA Post Approval Study
(2017, N>350)
Impella RP PAS
FDA Post Approval Study
(2017, N>66)
IQ Database
Real-World Data
(2009, N>50K)
Shock Working
GroupReal-World Data
(2015, N>2000)
IQ Database
Real-World Data
(2009, N>40K))
Pilot Best Practices:
RESTORE EF
US Investigator-Initiated
(2019, N>100)
DCSI—NCSI
US Investigator-Initiated
(2016, N>300)
Inova System
US Investigator-Initiated
(2016, N>304)
DanShock -
Danger
EU RCT
(2018, N>140)
High-Risk PCI Cardiogenic Shock
*MCS=Mechanical Circulatory Support
Class I Guidelines GoalBest Practice Impella Outcomes vs. Other Care
PROTECT IV
High-Risk PCI with
Planned Complete
Revascularization:
RECOVER IV
AMI Shock PCI:
Impella
Supported
PCI
PCI
Without
Planned
Hemodynamic
Support
Impella
Supported
pre-PCI
with
5.5/RP/
Oxygenation
Escalation
Other
Treatment
Protocols
Including
Any kind
MCS*
Excluding
Impella
devices
VS.
VS.
High-Risk PCI Cardiogenic Shock
3. Improving
Patient
OutcomesJP MORGAN 2021 | FOR INVESTORS ONLY
CLINICAL VALIDATION FROM RENOWNED PHYSICIANS
*Click physician image to be directed to their Investor presentation.
BEST PRACTICES IN HIGH-RISK PCIDr. Jason Wollmuth - Providence Heart
and Vascular Institute
“Complete revascularization in a single setting improves
patients’ quality of life due to improvement in LVEF”
SHOCK: SCIENCE OF UNLOADING
Dr. Navin Kapur - Tufts Medical Center
“LV unloading with Impella improves heart oxygenation levels,
even before a blocked artery is opened in the heart. LV
unloading with Impella protects mitochondria, which is
fundamental for heart recovery”
NCSI: BEST PRACTICES FOR SURVIVAL
AND NATIVE HEART RECOVERY
Dr. William O’Neill - Henry Ford Hospital
“We saw that the Impella placed prior to the angioplasty was
associated with an improvement in survival”
IMPELLA 5.5® AND ECPELLA™
Dr. Ed Soltesz - Cleveland Clinic Foundation
“The Impella 5.5 platform, especially when put in the axillary
position, allows us to recover the left ventricle and ambulate the
patient”
BREETHE’S ECMO OXY-1 SYSTEM™
Dr. Bart Griffith - University of Maryland
Medical Center
“ECpella (Impella and Breethe) will drive a paradigm shift in
patient care”
PROTECT III & RESTORE EF – TCT 2020Dr. Chuck Simonton - Abiomed, VP and CMO
“In PROTECT III, the patients that are PROTECT II-like, the
MACCE rates which is death, MI, repeat revascularization or stroke
is significantly improved over Impella from six years to seven years
ago. In addition, it's highly statistically superior to the outcomes
that were achieved with the balloon pump back in the PROTECT II
Study”
JP MORGAN 2021 | FOR INVESTORS ONLY
ABIOMED: THE HEART RECOVERY COMPANY20
RECOVERING HEARTS.
SAVING LIVES.®
4. Sustaining Long-Term Growth
Driven by Innovation and Strong
Execution
4. Sustaining
Long-Term
GrowthJP MORGAN 2021 | FOR INVESTORS ONLY
TECHNOLOGY DIRECTIONS21
Breaking the “small-bore barrier” with Impella devices compatible with small-bore access and closure techniques
With advanced algorithms and metrics for easier patient management
Using Cloud-based “AI” to provide predictive information about pump and patient metrics to help guide clinical decision making
SMALLER
SMARTER
MORE CONNECTED
4. Sustaining
Long-Term
GrowthJP MORGAN 2021 | FOR INVESTORS ONLY
TECHNOLOGY DIRECTIONS22
Breaking the “small-bore barrier” with Impella devices compatible with small-bore access and closure techniques
IMPELLA XR
SHEATHTM
IMPELLA
ECPTM
SMALLER
4. Sustaining
Long-Term
GrowthJP MORGAN 2021 | FOR INVESTORS ONLY
TECHNOLOGY DIRECTIONS23
SMARTASSIST®
with AI Algorithms
With advanced algorithms and metrics for easier patient management
SMARTER
4. Sustaining
Long-Term
GrowthJP MORGAN 2021 | FOR INVESTORS ONLY
TECHNOLOGY DIRECTIONS24
Using Cloud-based “AI” to provide predictive information about pump and patient metrics to help guide clinical decision making
MORE CONNECTEDGuide
Assess
Predict
IMPELLA
CONNECT®
4. Sustaining
Long-Term
GrowthJP MORGAN 2021 | FOR INVESTORS ONLY
TECHNOLOGY DIRECTIONS25
Breaking the “small-bore barrier” with Impella devices compatible with small-bore access and closure techniques
IMPELLA XR
SHEATHTM
IMPELLA
ECPTM
SMARTASSIST®
with AI AlgorithmsWith advanced algorithms and metrics for easier patient management
Using Cloud-based “AI” to provide predictive information about pump and patient metrics to help guide clinical decision making
SMALLER
SMARTER
MORE CONNECTED
Guide
Assess
Predict
IMPELLA
CONNECT®
4. Sustaining
Long-Term
GrowthJP MORGAN 2021 | FOR INVESTORS ONLY
IMPELLA INNOVATION AND SUSTAINABLE GROWTH26
GEOGRAPHIES
U.S.
296K PATIENTS
GERMANY
25K PATIENTS
JAPAN
50K PATIENTS
REST OF WORLD
MANY PATIENTS
INDICATIONS
CARDIOGENIC
SHOCK
RIGHT HEART /
BIVENTRICULAR
SUPPORT
HIGH-RISK PCI(PROTECTED PCI)
HEART FAILURE
(CLASS III & IV)
100K U.S.
PATIENTS
STEMI DTU(INFARCT REDUCTION)
>4M WW PATIENTS
RESPIRATORY
FAILURE
(ECMO)
NEW STUDIES
& INDICATIONS
TODAY
IMPELLA
2.5®
IMPELLA
ECPTM
PRODUCTS
IMPELLA
5.0®/LD®
IMPELLA
RP®
IMPELLA
CONNECT®
IMPELLA
CP®
with SmartAssist®
IMPELLA
5.5®
with SmartAssist®
IMPELLA
BTRTM
WEARABLE
DRIVER
IMPELLA XR
SHEATHTM
BREETHE OXY-1
SYSTEMTM
SMARTASSIST®
with AI Algorithms
FUTURE*
*IMPELLA ECPTM & IMPELLA BTRTM ARE IN DEVELOPMENT AND ARE NOT APPROVED FOR USE OR SALE. FUTURE ADDITIONAL
INDICATIONS AND STEMI ARE NOT APPROVED FOR USE.
4. Sustaining
Long-Term
GrowthJP MORGAN 2021 | FOR INVESTORS ONLY
IMPELLA INNOVATION AND SUSTAINABLE GROWTH27
*IMPELLA ECPTM & IMPELLA BTRTM ARE IN DEVELOPMENT AND ARE NOT APPROVED FOR USE OR SALE. FUTURE ADDITIONAL
INDICATIONS AND STEMI ARE NOT APPROVED FOR USE.
GEOGRAPHIES
REST OF WORLD
MANY PATIENTS
INDICATIONS
HEART FAILURE
(CLASS III & IV)
100K U.S.
PATIENTS
STEMI DTU(INFARCT REDUCTION)
>4M WW PATIENTS
RESPIRATORY
FAILURE
(ECMO)
NEW STUDIES
& INDICATIONS
FUTURE*
PRODUCTS
IMPELLA
ECPTM
IMPELLA
CONNECT®
IMPELLA
5.5®
with SmartAssist®
IMPELLA
BTRTM
WEARABLE
DRIVER
IMPELLA XR
SHEATHTM
BREETHE OXY-1
SYSTEMTM
SMARTASSIST®
with AI Algorithms
Recommended